Roche comes up short in its attempt to hold off generic competition to Esbriet

Roche’s blockbuster idiopathic pulmonary fibrosis drug Esbriet brings in more than $1 billion a year — and the Swiss pharma giant would like to keep it that way. Too bad a Delaware federal judge doesn’t agree.

US district judge Richard Andrews ruled on Tuesday that Novartis’ Sandoz unit didn’t infringe...

Click to view original post